Polyrizon Ltd. Intranasal Biotech Innovator

Polyrizon Ltd. (NASDAQ: PLRZ, name_ko: 포리라이즌) is a development-stage biotechnology company headquartered in Ra’anana, Israel. The company specializes in intranasal hydrogel medical devices designed to form a mucoadhesive barrier in the nasal cavity. Its proprietary Capture & Contain™ (C&C) technology serves as a barrier against viruses and allergens, while its Trap & Target™ (T&T) platform is in pre-clinical development for intranasal delivery of active pharmaceutical ingredients (APIs).

Intranasal Biotech by National Cancer Institute

Corporate Structure and Leadership

Polyrizon operates with a workforce of 2–10 employees, according to LinkedIn, and is guided by a leadership team with diverse expertise in pharmaceuticals, medical devices, and regulatory affairs:

• Tomer Izraeli, B.Sc, MBA – Founder & Chief Executive Officer with over 18 years in medical device and pharmaceutical development, sales, and business development.
• Nir Ben Yosef, CPA – Chief Financial Officer, former CFO of ENvizion Medical Ltd. and partner at Shimony Yosef CPA.
• Daphna Avital, MA – Chief People Officer, with over 20 years of experience in senior management positions at Allergan and AstraZeneca.
• Dr. Eyal S. Ron, Ph.D. – Chief Scientific Officer, co-founder of nine companies, and former affiliate at Harvard-MIT Health Sciences & Technology.
• Dr. Tidhar Turgeman, Ph.D. – Chief Technology Officer with a background in synthetic molecules and drug delivery systems.
• Asaf Azulay – Vice President, Regulatory Affairs & Quality Assurance, with over 20 years of experience specializing in regulatory strategy for medical devices.
• Sapir Abraham – Director, Regulatory Affairs & Quality Assurance, specializing in EU CE MDR and FDA 510(k) filings.

Recent Developments and News

On March 31, 2025, Polyrizon announced definitive agreements for a private placement, raising approximately $17.0 million through the sale of 35.4 million ordinary units (or pre-funded units) at $0.48 per unit. The net proceeds are designated for general corporate purposes and working capital.

Effective May 27, 2025, the company completed a 1-for-250 reverse share split on the Nasdaq Capital Market, reducing the number of shares from 1,332,083,023 to 5,328,332 while maintaining its authorized capital.

On May 23, 2025, Polyrizon received a notification from Nasdaq regarding a potential delisting linked to its March securities issuance. The company requested a hearing to address compliance concerns.

By July 15, 2025, a Nasdaq Hearings Panel affirmed Polyrizon’s continued listing under Listing Rule 5101, confirming its regulatory compliance.

In June 2025, Polyrizon entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S to provide clinical trial material for its PL-14 allergy-blocker nasal spray, in preparation for a clinical trial aimed at evaluating safety and efficacy in allergic populations in 2025.

A preliminary safety assessment using the MucilAir™ human nasal tissue model indicated that PL-14 maintained tissue viability and function over a four-hour period. This assessment is an important step ahead of the anticipated U.S. and European clinical trials in late 2025 or early 2026.

Financial and Strategic Analysis

Ticker	Exchange	Price (2025-07-15)	Change (%)	Volume
PLRZ	NASDAQ Capital Market (NAS)	$0.9358	+37.19%	6,304,421

The March private placement increased the company’s cash position to approximately $15.7 million post-warrant exercises. The reverse split and successful compliance measures aim to enhance share price stability and maintain Nasdaq listing. Polyrizon’s dual-platform strategy—C&C for barrier protection against inhaled threats and T&T for targeted API delivery—positions the company to pursue diverse regulatory and market opportunities, including allergy prevention and treatments for central nervous system conditions.

Market Position and Industry Context

Polyrizon operates within the realms of preventive healthcare and drug delivery. The C&C hydrogel provides protective measures against allergens and viruses in a preventive format. The T&T platform is positioned within markets such as acute repetitive seizures, which was valued at $3.15 billion in 2024, with an expected compound annual growth rate (CAGR) of 12.7% through 2030. Collaborations with academic institutions such as the Technion, Ben-Gurion University, and the University of Parma support its scientific advisory board and contribute to its translational development efforts.

TL;DR

On July 15, 2025, Polyrizon’s shares increased by 37.19% to $0.9358 after a Nasdaq Hearings Panel confirmed its continued listing. The company recently completed a $17.0 million private placement and a 1-for-250 reverse split (effective May 27, 2025) to reinforce liquidity and meet listing standards. Regulatory developments include a manufacturing agreement with Eurofins CDMO for clinical trial materials related to PL-14 and positive safety data from MucilAir™, setting the stage for clinical trials in late 2025 or early 2026. The company expects to remain funded for approximately 40 months and is advancing its Capture & Contain™ and Trap & Target™ platforms across allergy prevention and central nervous system treatment.